Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes

JAMA. 1995 Mar 15;273(11):871-5.


Standard statistical analyses of randomized clinical trials fail to provide a direct assessment of which treatment is superior or the probability of a clinically meaningful difference. A Bayesian analysis permits the calculation of the probability that a treatment is superior based on the observed data and prior beliefs. The subjectivity of prior beliefs in the Bayesian approach is not a liability, but rather explicitly allows different opinions to be formally expressed and evaluated. The usefulness of this approach is demonstrated using the results of the recent GUSTO study of various thrombolytic strategies in acute myocardial infarction. This analysis suggests that the clinical superiority of tissue-type plasminogen activator over streptokinase remains uncertain.

MeSH terms

  • Bayes Theorem*
  • Humans
  • Myocardial Infarction / drug therapy
  • Randomized Controlled Trials as Topic*
  • Streptokinase / therapeutic use
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator / therapeutic use


  • Streptokinase
  • Tissue Plasminogen Activator